IS5295A - Azetidínýlprópýlpíperidín afleiður, milliefni og notkun sem mótlyf gegn kínínhröðun - Google Patents

Azetidínýlprópýlpíperidín afleiður, milliefni og notkun sem mótlyf gegn kínínhröðun

Info

Publication number
IS5295A
IS5295A IS5295A IS5295A IS5295A IS 5295 A IS5295 A IS 5295A IS 5295 A IS5295 A IS 5295A IS 5295 A IS5295 A IS 5295A IS 5295 A IS5295 A IS 5295A
Authority
IS
Iceland
Prior art keywords
acetidinylpropylpiperidine
quinine
antagonists
intermediates
acceleration
Prior art date
Application number
IS5295A
Other languages
English (en)
Inventor
Victor Magee Thomas
Alker David
Nigel Maw Graham
Stuart Middleton Donald
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS5295A publication Critical patent/IS5295A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5295A 1997-07-04 1999-12-10 Azetidínýlprópýlpíperidín afleiður, milliefni og notkun sem mótlyf gegn kínínhröðun IS5295A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714129.5A GB9714129D0 (en) 1997-07-04 1997-07-04 Azetidines
PCT/EP1998/004177 WO1999001451A1 (en) 1997-07-04 1998-07-01 Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists

Publications (1)

Publication Number Publication Date
IS5295A true IS5295A (is) 1999-12-10

Family

ID=10815370

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5295A IS5295A (is) 1997-07-04 1999-12-10 Azetidínýlprópýlpíperidín afleiður, milliefni og notkun sem mótlyf gegn kínínhröðun

Country Status (36)

Country Link
US (1) US6262046B1 (is)
EP (1) EP1023285A1 (is)
JP (1) JP2000511207A (is)
KR (1) KR20010015532A (is)
CN (1) CN1261887A (is)
AP (1) AP1110A (is)
AR (1) AR013171A1 (is)
AU (1) AU726708B2 (is)
BG (1) BG103992A (is)
BR (1) BR9810544A (is)
CA (1) CA2294193A1 (is)
CO (1) CO4950604A1 (is)
DZ (1) DZ2550A1 (is)
EA (1) EA002773B1 (is)
GB (1) GB9714129D0 (is)
GT (1) GT199800106A (is)
HN (1) HN1998003689A (is)
HR (1) HRP20000002B1 (is)
HU (1) HUP0002330A3 (is)
ID (1) ID24090A (is)
IL (1) IL133433A0 (is)
IS (1) IS5295A (is)
MA (1) MA26519A1 (is)
NO (1) NO996115L (is)
NZ (1) NZ501715A (is)
OA (1) OA11236A (is)
PA (1) PA8454601A1 (is)
PE (1) PE83999A1 (is)
PL (1) PL338004A1 (is)
SK (1) SK182799A3 (is)
TN (1) TNSN98127A1 (is)
TR (1) TR200000025T2 (is)
TW (1) TW492960B (is)
UY (1) UY25079A1 (is)
WO (1) WO1999001451A1 (is)
ZA (1) ZA985875B (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
AU1089599A (en) * 1997-10-15 1999-05-03 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
FR2787449B3 (fr) 1998-12-15 2001-01-12 Sanofi Sa Derives de 3-phenyl-2,6-dioxopiperidin-3-yl propionamide et leur procede de preparation
FR2787448B3 (fr) 1998-12-18 2001-01-12 Sanofi Sa Ester d'alkyle inferieur de l'acide 3-(3,4-dihalogenophenyl) -2,6-dioxopiperidine3-propionique et son mode de preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
US6566356B2 (en) 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
CA2509406C (en) * 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
FR2876689B1 (fr) * 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
NZ556628A (en) * 2005-03-08 2009-09-25 Janssen Pharmaceutica Nv Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
JP2010535733A (ja) 2007-08-07 2010-11-25 エフ.ホフマン−ラ ロシュ アーゲー Nk3受容体アンタゴニストとしてのピロリジンアリールエーテル
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
KR102559211B1 (ko) 2015-06-23 2023-07-25 에자이 알앤드디 매니지먼트 가부시키가이샤 (6S,9aS)-N-벤질-8-({6-[3-(4-에틸피페라진-1-일)아제티딘-1-일]피리딘-2-일}메틸)-6-(2-플루오로-4-하이드록시벤질)-4,7-디옥소-2-(프로프-2-엔-1-일)헥사하이드로-2H-피라지노[2,1-c][1,2,4]트리아진-1(6H)-카복사마이드의 결정
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5625060A (en) 1991-05-03 1997-04-29 Elf Sanofi Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
GB9600235D0 (en) 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
GB9601697D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines

Also Published As

Publication number Publication date
ZA985875B (en) 2000-01-10
JP2000511207A (ja) 2000-08-29
EP1023285A1 (en) 2000-08-02
OA11236A (en) 2003-05-27
GB9714129D0 (en) 1997-09-10
DZ2550A1 (fr) 2003-02-08
PE83999A1 (es) 1999-09-11
TW492960B (en) 2002-07-01
AR013171A1 (es) 2000-12-13
AP9801291A0 (en) 1998-09-30
BR9810544A (pt) 2000-09-05
AU726708B2 (en) 2000-11-16
HUP0002330A2 (hu) 2001-06-28
BG103992A (en) 2000-07-31
GT199800106A (es) 2000-01-05
HRP20000002B1 (en) 2002-06-30
US6262046B1 (en) 2001-07-17
KR20010015532A (ko) 2001-02-26
EA002773B1 (ru) 2002-08-29
MA26519A1 (fr) 2004-12-20
CN1261887A (zh) 2000-08-02
HUP0002330A3 (en) 2002-05-28
CO4950604A1 (es) 2000-09-01
ID24090A (id) 2000-07-06
HN1998003689A (es) 1999-01-08
CA2294193A1 (en) 1999-01-14
SK182799A3 (en) 2001-11-06
TNSN98127A1 (fr) 2005-03-15
EA199901102A1 (ru) 2000-08-28
PA8454601A1 (es) 2000-05-24
UY25079A1 (es) 2000-12-29
IL133433A0 (en) 2001-04-30
WO1999001451A1 (en) 1999-01-14
NZ501715A (en) 2001-06-29
NO996115D0 (no) 1999-12-10
NO996115L (no) 2000-02-22
HRP20000002A2 (en) 2000-12-31
AP1110A (en) 2002-10-10
AU8806298A (en) 1999-01-25
PL338004A1 (en) 2000-09-25
TR200000025T2 (tr) 2000-06-21

Similar Documents

Publication Publication Date Title
DE60044873D1 (de) Orientierte biopolymermembrane
EE200200175A (et) Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
ID23338A (id) Popok tarik sekali pakai
ATE240327T1 (de) 1,2-annelierte chinolinderivate
ID26389A (id) Popok sekali pakai
EP0986385A4 (en) GONADORELIN ANTAGONISTS
FI19992171A7 (fi) Sprinkleri
IS5353A (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
ID23198A (id) Popok tarik sekali pakai
NO996115D0 (no) Azetidinylpropylpiperidin-derivater, intermediater og anvendelse som tachykinin-antagonister
DK15098A (da) Retningsbestemt mikrofon, især med symmetrisk retningsvirking
DK1437359T3 (da) Hidtil ukendte 3,6-hemiketaler fra 9a-azalidklassen
ID25571A (id) Popok sekali pakai
ID24782A (id) Popok sekali pakai
EE200200135A (et) D4 antagonistidena toimivad tienoisoksasolüül- jatienüülpürrasolüülfenoksü-asendatud propüülderivaadid
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
ID27845A (id) Turunan tetrahidrokuilina sebagai antagonis glisilina
PT964867E (pt) Antagonistas da taquicinima
NO20015068D0 (no) Nya 8A- og 9A-15-medlemmers laktamer
DE60018144D1 (de) Wälzelement
DE60005282D1 (de) Golfschlägerkopf, golfschläger und golfschlägerset
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
NO20013625L (no) Megsinpromotor
ATA114799A (de) Abseilgerät
TR199701646A3 (tr) Vitronektin-reseptör antagonistleri,üretimleri ve kullanimlari